In the subgroup of men with T2DM with more than 1 year disease duration, we found no decrease in risk of prostate cancer for men on metformin and a weak decrease in risk for men on insulin/sulfonylurea compared to men with T2DM not on anti‐diabetic drugs. The gene discussed is INS; the disease is prostate cancer.